一家前三季度盈利177万元的上市公司，试图给总裁涨薪40%至91万元未果。 证券时报·e公司记者注意到，在12月30日举行的交大昂立（600530）2025年第二次临时股东会上，《关 于调整总裁岗位基本薪酬的议案》（下称"《总裁调薪议案》"）遭否决。 交大昂立现任总裁为嵇霖。嵇霖出生于1968年，其同时也是交大昂立的实际控制人。根据公开资料分 析，嵇霖间接控制的交大昂立股票市值超过14亿元。 公司前三季度仅盈利177万元 此前，交大昂立于12月8日召开董事会审议通过了《总裁调薪议案》。上市公司称，其总裁目前岗位基 本薪酬为2016年第六届董事会第八次会议审议通过，多年未曾调整，已不符合现有市场薪资行情。按照 公司所处行业和规模，结合公司的实际经营情况及现有市场薪资行情，根据职位价值、所承担的责任、 能力等因素综合确定，公司总裁岗位基本薪酬由65万元/年调整为91万元/年；岗位基本薪酬作为年度基 薪，按月取得基薪的1/12，自2025年9月1日起予以计发。 在董事会表决中，3名关联董事回避表决，《总裁调薪议案》以"3票同意、反对0票、弃权0票"获得审议 通过。 根据股东大会的表决结果，《总裁调薪议案》获得同意票 ...

Core Viewpoint - The company, Jiaoda Onlly (交大昂立), reported a decline in both revenue and net profit for the first half of 2025, alongside being under investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations [1][2]. Financial Performance - The company achieved a revenue of 151 million yuan, a year-on-year decrease of 5.77% [1]. - The net profit attributable to shareholders was 2.25 million yuan, down 30.54% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was -2.13 million yuan, indicating an increase in losses compared to the previous year [1]. Business Segments - The main business areas of the company include the research, production, and sales of health products, as well as the operation and management of elderly medical care institutions [1]. - In the 2024 annual report, the revenue contributions from health products, real estate, and medical care businesses were 48.45%, 5.01%, and 45.33%, respectively [1]. Challenges and Legal Issues - The health product segment faced a slight decline due to intensified competition in the domestic probiotic industry and changes in tariff policies in North America [2]. - The medical care segment has encountered issues as various non-profit institutions unilaterally terminated management consulting agreements and refused to pay management fees, leading the company to file lawsuits [2]. - The company received a notice from the CSRC regarding an investigation for suspected violations of information disclosure laws [2].

Group 1 - The core issue is that Jiaoda Onlly has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [2] - The company received a regulatory letter from the Shanghai Stock Exchange regarding various issues, including its small loan business and discrepancies in sales revenue and expenses [4] - The company reported significant financial impacts from a debt transfer agreement involving its subsidiary, which was not disclosed in a timely manner [5] Group 2 - Jiaoda Onlly's main business includes the research, production, and sales of health products and the management of elderly care institutions [6] - The company has faced challenges in recent years, with reported net losses of approximately 498 million yuan in 2022 and 35.08 million yuan in 2023, but is projected to return to profitability in 2024 with an estimated net profit of 30.48 million yuan [8] - In the first quarter of 2025, the company experienced a revenue decline of 2.83% and a net loss of 6.88 million yuan, indicating ongoing financial difficulties [11] Group 3 - The stock price of Jiaoda Onlly has seen significant volatility, increasing from 4.52 yuan per share to 9.51 yuan per share, resulting in a market capitalization of 7.4 billion yuan as of July 11 [11] - The chairman of the company has emphasized accountability for the actions of former executives involved in illegal activities, indicating a commitment to protecting shareholder interests [8]

Core Viewpoint - The company Jiaoda Anli is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which has raised concerns about its financial practices and governance [2]. Group 1: Regulatory Issues - On July 11, Jiaoda Anli received a notice from the CSRC regarding the initiation of an investigation due to suspected information disclosure violations [2]. - The Shanghai Stock Exchange previously issued a regulatory letter to Jiaoda Anli, questioning various aspects of its financial reporting, including small loan business practices and discrepancies in sales revenue and expenses [5][6]. - The company was required to explain the decision-making process behind a debt transfer agreement involving a subsidiary and a joint venture, which significantly impacted its net profit [7]. Group 2: Financial Performance - Jiaoda Anli has faced financial difficulties in recent years, reporting net losses of approximately 498 million yuan in 2022 and 35.08 million yuan in 2023 [10]. - In 2024, the company managed to turn a profit with a net income of about 30.48 million yuan [10]. - However, in the first quarter of 2025, the company reported a revenue decline of 2.83% and a net loss of 6.88 million yuan, indicating ongoing financial challenges [11]. Group 3: Corporate Governance - The company has been involved in legal actions against five former executives for alleged illegal activities related to insurance purchases, although the case has not progressed to criminal charges [10]. - The chairman of Jiaoda Anli emphasized the commitment to hold former executives accountable and protect the interests of the company and its shareholders [10]. Group 4: Market Performance - Following the announcement of its financial results on April 29, the company's stock price increased significantly, rising from 4.52 yuan per share to 9.51 yuan per share by July 11, reflecting a doubling in value and a market capitalization of 7.4 billion yuan [11].